Table 1 Clinical characteristics of patients
TLE + HS | TLE-HS | XLE | IGE | |
|---|---|---|---|---|
n | 34 | 105 | 95 | 36 |
Female | 21 (61.8) | 48 (45.7) | 49 (51.6) | 22 (61.1) |
Age, years | 45.1 (13.4) | 40.6 (13.9) | 37.0 (14.2) | 30.7 (12.1) |
Age at onset, years | 12.9 (9.5) | 18.7 (13.1) | 16.2 (15.5) | 13.9 (7.0) |
Known remote symptomatic aetiology | ||||
Known aetiology | 34 (100) | 60 (57.1) | 57 (60.0) | 0 |
Genetic | 0 | 0 | 0 | 36 (100) |
Duration of epilepsy, years | 32.1 (14.9) | 22.4 (16.9) | 20.8 (14.3) | 16.6 (11.8) |
Patients who fulfilled the criteria for refractory epilepsy | 32 (94.1) | 89 (84.8) | 83 (87.4) | 28 (77.8) |
Seizure-free patients for 1 year before labs | 3 (8.8) | 17 (16.1) | 15 (15.7) | 15 (41.6) |
At least one seizure 1 month before labs | 25 (73.5) | 69 (65.7) | 60 (63.2) | 14 (38.9) |
Seizure frequency 1 month before labs | 2.9 (2.9) | 4.7 (10.0) | 7.7 (15.0) | 0.8 (1.4) |
Autoimmune disease | 5 (14.7) | 10 (9.5) | 6 (6.3) | 2 (5.6) |
Surgery | ||||
No surgery | 26 (76.5) | 84 (80.0) | 82 (86.3) | 36 |
Epilepsy surgery | 8 (23.5) | 11 (10.5) | 2 (2.1) | 0 |
Other lesional surgery | 0 | 10 (9.5) | 11 (11.5) | 0 |